M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover Pharmaceutical TechnologyThis acquisition marks Eli Lilly's first move into the psychedelic space as the pharma curates a diversified pipeline.NeuroscienceRead full story pharminent July 16, 2026 (Last updated: July 17, 2026) Pharmaceutical Technology This acquisition marks Eli Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: J&J Beats Q2 Estimates, Raises Full-Year Guidance on Innovative Medicine StrengthNext: FDA Approves At-Home Leqembi for Early Alzheimer’s Disease Related Stories M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026 M&A / Deals Novartis and Chai Discovery collaborate on antibody identification pharminent July 14, 2026
